Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Zhentian Kai"'
Autor:
Haihua Huang, Zhentian Kai, Yuchen Wang, Xiaomiao Zhang, Jin Wang, Wei Zhang, Qian Xue, Hang Zhang, Hansong Jin, Peize Meng, Shuilong Zhang, Yueyue Yang, Honghua Yang, Wanning Liang, Guangbing Zha, Peng Luo, Yan Xu, Weiwei Shi, Zheng Ruan
Publikováno v:
Cancer Medicine, Vol 13, Iss 10, Pp n/a-n/a (2024)
Abstract Circulating tumor DNA (ctDNA) has been widely used as a minimally invasive biomarker in clinical routine. However, a number of factors such as panel design, sample quality, patients' disease stages are known to influence ctDNA detection sens
Externí odkaz:
https://doaj.org/article/e92d4f67a1b54181bc5def0c14e83cf0
Autor:
Ran Zhao, Dongge Xia, Yingwei Chen, Zhentian Kai, Fangying Ruan, Chaoran Xia, Jingkai Gong, Jun Wu, Xueliang Wang
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 14636-14645 (2023)
Abstract Background Conventional blood and stool tests are normally used for early screening of colorectal cancer (CRC) but the accuracy and efficiency remain to be improved. Recent findings suggest Fusobacterium nucleatum to be a biomarker for CRC.
Externí odkaz:
https://doaj.org/article/5983b4158303424ebf35f3e9eeca7ac3
Autor:
Ran Zhao, Dongge Xia, Yingwei Chen, Zhentian Kai, Fangying Ruan, Chaoran Xia, Jingkai Gong, Jun Wu, Xueliang Wang
Publikováno v:
Cancer Medicine.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53e0ce52ed9a8f7ce1225cc87116b983
https://doi.org/10.1002/cam4.6067
https://doi.org/10.1002/cam4.6067
Publikováno v:
Journal of Clinical Oncology. 40:e17561-e17561
e17561 Background: HRD test from Myriad Inc. was approved by FDA as a biomarker for niraparib in ovarian cancer. Its threshold (as 42) was initially established by capturing 95% of tumors with BRCA1/2 mutation and BRCA1 promoter methylation in the tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f517afdf6762b7c85c64f40914ac7d9
https://doi.org/10.1200/jco.2022.40.16_suppl.e17561
https://doi.org/10.1200/jco.2022.40.16_suppl.e17561
Autor:
null Xiaopei, Lei Li, Zhentian Kai, Lisha Huang, Ruijue Lin, Peng Luo, Hongsheng He, Lijun Cai
Publikováno v:
Proceedings of the 7th Biennial Meeting of Asian Society of Gynecologic Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3840c6e848b2853caad778d05099e18
https://doi.org/10.3802/jgo.2021.32.s1.o04
https://doi.org/10.3802/jgo.2021.32.s1.o04
SUMMARYWhole genome sequencing (WGS) is championed by the UK National Health Service (NHS) to identify genetic variants that cause particular diseases. The full potential of WGS has yet to be realised as early data analytic steps prioritise protein-c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c444b1d4223e7ce6f0a94ac4b0a1347c
https://doi.org/10.1101/2020.03.30.20047209
https://doi.org/10.1101/2020.03.30.20047209
